nomacopan
Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy (HSCT-TMA)
Key Facts
About Akari Therapeutics
Akari Therapeutics is a micro-cap, clinical-stage biotech with a singular focus on its dual-mechanism drug, nomacopan. The company is targeting severe, rare inflammatory disorders with high unmet need, specifically through programs in HSCT-TMA and bullous pemphigoid. With a valuation of approximately $10 million and a stock price near its 52-week low, the company faces significant financial and clinical execution risks. Its future is heavily dependent on the success of nomacopan in ongoing and future trials, requiring additional capital to reach key milestones.
View full company profileAbout Akari Therapeutics
Akari Therapeutics is a micro-cap, clinical-stage biotech with a singular focus on its dual-mechanism drug, nomacopan. The company is targeting severe, rare inflammatory disorders with high unmet need, specifically through programs in HSCT-TMA and bullous pemphigoid. With a valuation of approximately $10 million and a stock price near its 52-week low, the company faces significant financial and clinical execution risks. Its future is heavily dependent on the success of nomacopan in ongoing and future trials, requiring additional capital to reach key milestones.
View full company profile